Rapport Therapeutics (NASDAQ:RAPP) & Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Head-To-Head Survey

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) and Rapport Therapeutics (NASDAQ:RAPP) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares Recordati Industria Chimica E Farmaceutica and Rapport Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.96 billion	4.10	$501.92 million	$2.80	21.00
Rapport Therapeutics	N/A	N/A	-$111.48 million	($3.04)	-8.24

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Recordati Industria Chimica E Farmaceutica and Rapport Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	0	1	0	1	3.00
Rapport Therapeutics	1	0	13	2	3.00

Rapport Therapeutics has a consensus price target of $68.36, indicating a potential upside of 172.91%. Given Rapport Therapeutics’ higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Recordati Industria Chimica E Farmaceutica.

Volatility & Risk

Recordati Industria Chimica E Farmaceutica has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Rapport Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and Rapport Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	18.38%	33.73%	12.76%
Rapport Therapeutics	N/A	-29.02%	-27.37%

Summary

Recordati Industria Chimica E Farmaceutica beats Rapport Therapeutics on 7 of the 11 factors compared between the two stocks.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.